ArticleESMO open2017
Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer.
Article in ESMO open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Health state utility values by cancer stage: a systematic literature review.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Pooled it
- Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe.Breast (Edinburgh, Scotland) · 2021Pooled it
- Relationship between social support, physical symptoms, and depression in women with breast cancer and pain.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Social wellbeing in older breast cancer survivors taking adjuvant endocrine therapy: impacts of self-efficacy for symptom management and pain.Frontiers in aging · 2026Article
- Impact of pain on functional status and quality of life in Jordanian women with breast cancer.PloS one · 2024Article
- Role of sex hormones in modulating breast and ovarian cancer associated pain.Molecular and cellular endocrinology · 2021Article
- Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.BMC cancer · 2020Article
- How I treat cancer special issue.ESMO open · 2019Article
- The Effect of 5-Min Mindful Breathing on Pain in Palliative Care Cancer Patients: A Randomized Controlled Study.Indian journal of palliative careArticle
- A Systematic Review: Mindfulness Intervention for Cancer-Related Pain.Asia-Pacific journal of oncology nursingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatient-reported pain severity and related impact in advanced/metastatic breast cancer (ABC/MBC) are not well documented. The objective of this study was to assess pain and general health status in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) ABC/MBC.
methodsData were collected in the USA and Europe in a real-world, cross-sectional study. Patients were recruited at oncology practices and completed validated questionnaires; pain severity and interference were assessed using the Brief Pain Inventory (BPI) and general health status using the EuroQoL-5D (EQ-5D-3L). Descriptive statistics were generated for the overall cohort, and stratified by type of therapy and sites of metastases. Differences between patient groups were assessed via the Mann-Whitney Wilcoxon test. The relationship between pain scores and general health status was assessed using Kruskal-Wallis tests.
resultsOverall, 173 oncologists and 739 patients participated. The majority of patients rated their worst pain, average pain and pain interference as mild (59%, 77% and 70%, respectively). Most patients (>90%) reported no problems or moderate problems for all items of the EQ-5D-3L. Current treatment had no significant associations with pain severity or interference. Patients on chemotherapy reported significantly higher proportions of moderate/extreme levels of anxiety/depression (66.7%) and significantly lower general health status (60.7) compared with those on endocrine therapy (53.1% and 64.4, respectively). Pain severity and interference, all EQ-5D-3L items except self-care and the EQ-5D-3L health utility index were also significantly associated with sites of metastases, with greater impact in patients with visceral and bone metastases than those with bone only or visceral only metastases. Significant associations were observed between pain and health status, with increased pain severity and pain interference associated with worse health utility and general health status.
conclusionThere is a clear unmet need for treatments that can reduce pain and preserve health status in patients with HR+/HER2- ABC/MBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.